A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects

This is an open-label, single-dose, parallel-group study to evaluate the safety, tolerability and pharmacokinetic characteristics of LY03015 in healthy Chinese and Caucasian adult subjects. The duration of study will be around up to 42 days for each participant, including up to 14 days of screening period, baseline visit, and a 28-day safety assessment period with a 7-day/6-night stay in the clinical research unit.

NCT Number	NCT07671833
Lead Sponsor	Luye Pharma Group Ltd.
Conditions	Healthy Participants
Enrollment	24 participants
Start Date	2026-04-15
Primary Completion	2026-05-08 (estimated)
Study Completion	2026-05-27 (estimated)
Updated on ClinicalTrials.gov	2026-06-26